ClinicalTrials.gg
Active, not recruitingNCT05648500OPUS-1Updated Oct 30, 2026

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

A Phase 3 interventional study of Cenerimod and Placebo in Lupus Erythematosus, Systemic, sponsored by Viatris Innovation GmbH. Active, not recruiting at 198 sites in 17 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Viatris Innovation GmbH (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
470
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 74 studies in Lupus Erythematosus, Systemic with a site in Japan — 18 open to participants now, 34 under way, 16 of them phase 3. Lupus Erythematosus, Systemic · Japan.

Enrollment
15th of 70
470 · median 259
Started
2022
with 7 others
Phase 3
27 of 74
8 open now
Primary completion
2027-03
later than 8 of 33 live
Registered
53rd of 74
by date

Among the 74 studies in Lupus Erythematosus, Systemic with a site in Japan, this one is the 15th largest by enrollment of the 70 interventional ones that give a count, is one of 8 that started in 2022, is one of 27 in phase 3, reaches primary completion later than 8 of the 33 other live ones, and was the 53rd registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

18 of the 74 studies in Lupus Erythematosus, Systemic with a site in Japan are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 74 studies in Lupus Erythematosus, Systemic with a site in Japan, or all of them as a file.
02

Study summary

The goal of this clinical trial is to see how well cenerimod reduces symptoms of Systemic Lupus Erythematosus in adult patients with moderate to severe symptoms. The main questions it aims to answer are:

  • How well cenerimod works on top of the treatment already being administered.
  • How safe cenerimod is for adult patients with Systemic Lupus Erythematosus.

Researchers will compare one dose of cenerimod and a placebo to see how well cenerimod works when it is added to the treatment already being administered.

In this research study approximately 210 participants will receive cenerimod and approximately 210 participants will receive placebo for 12 months.

03

Conditions studied

  • Lupus Erythematosus, Systemic

Keywords

  • Musculoskeletal and connective tissue disorders
  • Connective Tissue Diseases
  • Immune System Diseases
  • Autoimmune Diseases
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Inclusion criteria at screening:

  • Signed Form (ICF) prior to any study-mandated procedure.
  • Diagnosis of Systemic Lupus Erythematosus (SLE) made at least 6 months prior to Screening, according to 2019 European League Against Rheumatism / American College of Rheumatology Criteria.
  • A modified Systemic Lupus Erythematosus Disease Activity Index-2000 (mSLEDAI-2K) score ≥ 6 and clinical mSLEDAI-2K score ≥ 4 with at least 2 points for musculoskeletal or mucocutaneous manifestations (i.e., myositis, arthritis, rash, alopecia, mucosal ulcers). The mSLEDAI-2K score does not include "leukopenia".
  • British Isles Lupus Assessment Group-2004 (BILAG) Grade B in ≥ 2 organ systems or a BILAG Grade A in ≥ 1 organ system.
  • Physician's Global Assessment (PGA) score ≥ 1.0 on a 0 to 3 visual analog scale.
  • Currently treated with one or more of the following SLE background medications:

    • Anti-malarials (≤ 400 mg/day hydroxychloroquine, ≤ 500 mg/day chloroquine, ≤ 100 mg/day quinacrine).
    • Mycophenolate mofetil (≤ 2 g/day) / mycophenolic acid (≤1.44 g/day).
    • Azathioprine (≤ 2 mg/kg/day).
    • Methotrexate (≤ 25 mg/week).
    • Oral (OCS):

      • if OCS is the only SLE background medication: ≥ 7.5 mg/day and ≤ 30 mg/day prednisone or equivalent.
      • if OCS is not the only SLE background medication: ≤ 30 mg/day prednisone or equivalent.
    • Belimumab (≤10 mg/kg every 4 weeks intravenously [i.v.], or 200 mg/week subcutaneously [s.c.]).

Treatment with antimalarials, mycophenolate mofetil, mycophenolic acid, azathioprine, methotrexate or belimumab must have been started at least 90 days prior to Screening. Treatment with OCS must have been started at least 30 days prior to Screening.

  • For women of (WoCBP):
  • Negative serum pregnancy test at Screening.
  • Agreement to undertake monthly urine pregnancy tests from Randomization up to 6 months after study treatment discontinuation.
  • Agreement to use a highly effective method of from Screening (Visit 1) up to 6 months after study treatment discontinuation.

Inclusion criteria at randomization:

  • A clinical mSLEDAI-2K score ≥ 4 with at least 2 points for musculoskeletal or mucocutaneous manifestations (i.e., myositis, arthritis, rash, alopecia, mucosal ulcers).
  • BILAG Grade B in 2 or more organ systems or a BILAG Grade A in 1 or more organ system.
  • PGA score ≥ 1.0 on a 0 to 3 visual analog scale.
  • Presence of at least one of the following biomarkers of serological evidence of active SLE (in a Screening sample as measured by central laboratory):

    • Anti-dsDNA antibodies elevated above normal,
    • Antinuclear antibodies with a titer of at least 1:160,
    • Anti-Smith antibody elevated above normal.
  • Currently treated with one or more of the following SLE background medications that must be stable for at least 30 days prior to Randomization (except OCS, which must be stable for at least 15 days prior to Randomization):

    • Antimalarials (≤ 400 mg/day hydroxychloroquine, ≤ 500 mg/day chloroquine, ≤ 100 mg/day quinacrine);
    • Mycophenolate mofetil (≤ 2 g/day) / mycophenolic acid (≤ 1.44g/day);
    • Azathioprine (≤ 2 mg/kg/day);
    • Methotrexate (≤ 25 mg/week);
    • OCS:

      • if OCS is the only SLE background medication: ≥ 7.5 mg/day and ≤ 30 mg/day prednisone or equivalent.
      • if OCS is not the only SLE background medication: ≤ 30 mg/day prednisone or equivalent.
    • Belimumab (≤ 10 mg/kg every 4 weeks i.v. or ≤ 200 mg/week s.c.).
  • WoCBP must have a negative urine pregnancy test at Randomization.

Main Exclusion Criteria:

  • Pregnant, planning to be become pregnant up to Final Study Visit, or lactating women.
  • Severe active central nervous system lupus or active severe or unstable neuropsychiatric SLE including but not limited to: aseptic meningitis; cerebral vasculitis; myelopathy; demyelination syndromes (ascending, transverse, acute inflammatory demyelinating polyradiculopathy); acute confusional state; impaired level of consciousness; psychosis; acute stroke or stroke syndrome; cranial neuropathy; status epilepticus; cerebellar ataxia; or mononeuritis multiplex:

    • That would make the subject unable to fully understand the ICF; OR
    • Where, in the opinion of the investigator/delegate, protocol-specified standard of care is insufficient and the use of a more aggressive therapeutic approach, such as adding i.v. cyclophosphamide and/or high dose i.v. pulse corticosteroid (CS) therapy or other treatments not permitted in the protocol is indicated.
  • A diagnosis of mixed connective tissue disease or any history of overlap syndromes of SLE with psoriasis, rheumatoid arthritis, erosive arthritis, scleroderma, hepatitis or uncontrolled autoimmune thyroid disease.
  • History or presence of Mobitz type II or third-degree atrioventricular block, sick sinus syndrome, symptomatic bradycardia or syncope associated with cardiac disorders.
  • Subjects who experienced myocardial infarction, unstable angina pectoris, stroke, , vascular thrombosis, decompensated heart failure requiring hospitalization, or heart failure defined by the Class III/IV within 6 months prior to Screening.
  • Resting heart rate \< 50 bpm as measured by the 12-lead at Screening or at Randomization.
  • An elevated corrected according to Fridericia's formula (QTcF) interval of > 470 ms (females) / > 450 ms (males) at Screening or at Randomization.
  • History or presence of severe respiratory disease or pulmonary fibrosis, based on medical history, lung function, and chest X-ray (or CT scan as per local guidelines), performed at Screening or within 6 months prior to Screening.
  • History of bronchial asthma or that has required treatment with oral or parenteral CS for more than a total of 2 weeks within the last 6 months prior to Screening.
  • History or presence of (except for surgically excised and non-recurrent cutaneous basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma), lymphoproliferative disease, or history of total lymphoid irradiation within 10 years prior to Screening.
  • Presence of any of the following abnormalities detected during the ophthalmological evaluation and/or by optical coherence tomography (OCT) during screening:

    • Macular edema of any cause: diabetic, cystoid, tractional.
    • Foveal degeneration, macular hole, macular pseudohole, hereditary or degenerative maculopathies.
    • Active uveitis, papilledema.
    • Retinal neovascularization of any cause and in any location.
  • History of chronic liver or biliary disease (other than Gilbert's Syndrome) or subjects with or aspartate aminotransferase > 3 × (ULN) or total > 1.5 × ULN (unless in the context of known Gilbert's Syndrome).
  • Significant hematology abnormality at screening assessment:

    • lymphocyte count \< 500 /μL (0.5 × 10\^9/L);
    • \< 7 g/dL;
    • white blood cell count \< 2000/μL (2.0 × 10\^9/L); or
    • \< 25000/μL (25 × 10\^9/L).
  • Estimated \< 15 mL/min/1.73 m\^2.
  • Treatment with the following medications within 15 days or 5 half-lives of the medication (whichever is longer) prior to Randomization:

    • β-blockers, diltiazem, verapamil, digoxin, digitoxin, or any other anti-arrhythmic or heart-rate -lowering systemic therapy.
    • QT-prolonging drugs with known risk of torsade de pointes irrespective of indication.
  • Treatment with the following medications within 30 days or 5 half-lives of the medication (whichever is longer) prior to Randomization:

    • Cyclophosphamide, cyclosporine, voclosporin, tacrolimus, sirolimus, etc.
    • Pulse methylprednisolone.
    • Vaccination with (including live vaccines for COVID-19).
  • Intra-articular, intramuscular or i.v. CS within 6 weeks prior to Randomization.
  • Treatment with the following medications within 90 days or 5 half-lives of the medication (whichever is longer) prior to Randomization:

    • Leflunomide.
    • i.v. immunoglobulins.
  • Treatment with any agent within 90 days or 5 half-lives of the drug (whichever is longer) prior to Randomization.
  • Treatment with B cell-depleting biological agents (e.g., rituximab or ocrelizumab) or biological agents (e.g., anti-tumor necrosis factor [TNF], anti-interleukin [IL]-1, anti-IL6 therapies), within 12 months prior to Randomization.
  • Treatment with anifrolumab within 6 months prior to Randomization.
  • Treatment with any of the following medications any time prior to Screening:

    • Alemtuzumab,
    • Sphingosine-1-phosphate receptor modulators (e.g., fingolimod),
    • Subjects previously randomized to cenerimod or placebo in any trial involving cenerimod.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
470 participants (actual)

Study arms

  • Experimental
    Cenerimod 4 mg

    Participants will receive cenerimod once daily in addition to background SLE therapy.

    Drug: Cenerimod

  • Placebo comparator
    Matching placebo

    Participants will receive matching placebo once daily in addition to background SLE therapy.

    Drug: Placebo

Interventions

  • Cenerimod will be supplied as a film-coated tablets at the dose of 4 mg.

    Also known as: ACT-334441

  • DrugPlacebo

    Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod.

06

What researchers measure

Primary outcomes

  1. Response on Systemic Lupus Erythematosus Responder Index 4 (SRI-4) at Month 12 compared to baseline

    Response on SRI-4 is defined as: * Reduction from baseline of at least 4 points in the modified Systemic Lupus Erythematosus Disease Activity Index-2000 score (mSLEDAI-2K \[SLEDAI-2K modified to exclude leukopenia, thus mSLEDAI-2K\]), and * No new British Isles Lupus Assessment Group-2004 (BILAG) A organ domain score and not more than one new BILAG B organ domain score compared to baseline, and * No worsening from baseline in subjects' lupus disease activity, where worsening is defined as an increase ≥ 0.30 points on a 3-point Physician's Global Assessment visual analog scale (PGA VAS), and * No violation of specified medication rules detailed in the core protocol.

    Time frame: At Month 12 compared to Day 1 (pre-dose baseline)

Secondary outcomes

  1. Response on BILAG-based Composite Lupus Assessment (BICLA) at Month 12 compared to baseline

    Response on BICLA is defined as: * Improvement from baseline in disease activity as measured by BILAG. Improvement is defined as a reduction of all baseline BILAG A to B/C/D and baseline BILAG B to C/D and no BILAG worsening in other organ systems, where worsening is defined as ≥ 1 new BILAG A or ≥ 2 new BILAG B, and * No worsening from baseline in mSLEDAI-2K, where worsening is defined as an increase from baseline of \> 0 points in mSLEDAI-2K, and * No worsening from baseline in the patient's lupus disease activity, where worsening is defined as an increase of ≥ 0.30 points on a 3-point PGA VAS, and * No discontinuation of investigational product, and * No violation of specified medication rules detailed in the core protocol.

    Time frame: At Month 12 compared to Day 1 (pre-dose baseline)

  2. Time to first confirmation of a 4-month sustained modified Systemic Lupus Erythematosus Disease Activity Index-2000 (mSLEDAI-2K) response

    A response is defined as a reduction of at least 4 points from baseline.

    Time frame: Day 1 (pre-dose baseline) to Month 12

  3. Steroid sparing effect in the subgroup of subjects with baseline OCS dose ≥ 10 mg/day prednisone or equivalent

    Response is defined as meeting all of the following: * Achieve an OCS dose of ≤ 7.5 mg/day prednisone or equivalent by Month 9. * Maintain an OCS dose ≤ 7.5 mg/day prednisone or equivalent from Month 9 to Month 12. * No violation of pre-specified medication rules detailed in the core protocol.

    Time frame: Day 1 (pre-dose baseline) to Month 12

  4. Response at Month 12 in Lupus Low Disease Activity State (LLDAS)

    response is defined as: * mSLEDAI-2K ≤ 4 (with no activity in major organ systems, i.e., renal, central nervous system, cardiopulmonary, vasculitis and fever). * No new features of lupus disease activity compared with the previous assessment. * PGA ≤ 1. * Current prednisone-equivalent dosage ≤ 7.5 mg/day. * Well tolerated standard maintenance dosages of immunosuppressive drugs and approved biologics.

    Time frame: Day 1 (pre-dose baseline) to Month 12

07

Study locations

198 sites

Showing the first 100 of 198 sites across 17 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Askanase AD, D'Cruz D, Kalunian K, Merrill JT, Navarra SV, Cahuzac C, Cornelisse P, Murphy MJ, Strasser DS, Trokan L, Berkani O. Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Rheumatol. 2025 Jan;7(1):e21-e32. doi: 10.1016/S2665-9913(24)00246-7. Epub 2024 Nov 22. PubMed 39586304 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Mar 2027, 51 months after the start.

Of 53 phase 3 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 84. This study's planned 51 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2022
First posted
Dec 13, 2022
StartActual
Dec 13, 2022
Primary completionEst.
Mar 31, 2027
CompletionEst.
Sep 30, 2027
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Secondary outcomes
2 added, 1 removed
What changed in the outcomes
  • AddedSteroid sparing effect in the subgroup of subjects with baseline OCS dose ≥ 10 mg/day prednisone or equivalentTime frame: Day 1 (pre-dose baseline) to Month 12
  • AddedResponse at Month 12 in Lupus Low Disease Activity State (LLDAS)Time frame: Day 1 (pre-dose baseline) to Month 12
  • RemovedTime to first confirmation of a 4-month sustained response in mucocutaneous manifestations (i.e., rash, alopecia, mucosal ulcers)Time frame: Day 1 (pre-dose baseline) to Month 12
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Secondary outcomes 2 added, 1 removed
    What changed in the outcomes
    • AddedSteroid sparing effect in the subgroup of subjects with baseline OCS dose ≥ 10 mg/day prednisone or equivalentTime frame: Day 1 (pre-dose baseline) to Month 12
    • AddedResponse at Month 12 in Lupus Low Disease Activity State (LLDAS)Time frame: Day 1 (pre-dose baseline) to Month 12
    • RemovedTime to first confirmation of a 4-month sustained response in mucocutaneous manifestations (i.e., rash, alopecia, mucosal ulcers)Time frame: Day 1 (pre-dose baseline) to Month 12
    + 1 other change: site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05648500
Responsible party
Sponsor
First posted
Dec 13, 2022
Start date
Dec 13, 2022
Primary completion
Mar 31, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Oct 30, 2026

Study contacts

Clinical Trials
study director · Viatris Innovation GmbH

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cenerimod

Start the discussion